A Single Center, Multiple-dose, Non-randomized, Dose Adjustment, Open-Label Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Tolerability of Oshadi Icp in Patients With Type 1 Diabetes Mellitus -A Phase II Clinical Study
Phase of Trial: Phase II
Latest Information Update: 23 Apr 2018
Price : $35 *
At a glance
- Drugs Insulin (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Sponsors Oshadi Drug Administration
- 16 Apr 2018 Status changed from recruiting to completed.
- 28 Mar 2016 Planned End Date changed from 1 Oct 2016 to 1 Jun 2017 as per ClinicalTrials.gov record.
- 28 Mar 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Feb 2017 as per ClinicalTrials.gov record.